Navigation Links
BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Date:5/3/2011

NOVATO, Calif., May 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 10, 2011 at 2:20 p.m. PT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces First Quarter 2011 Financial Results
2. BioMarin to Present at the Deutsche Bank Healthcare Conference
3. BioMarin to Present at the Barclays Global Healthcare Conference
4. BioMarin to Present at the Cowen Health Care Conference
5. BioMarin to Present at the Citi Global Healthcare Conference
6. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
8. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
10. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
11. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... ... DC ... th – Monday, September 18 th .The Brain Tumor Foundation (BTF) ... to the public.Where:  BTF,s Mobile MRI Unit – ... NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... to announce the next generation for LASIK in Manhattan with Contoura Vision, the ... technologically advanced laser systems available in the United States to correct nearsightedness and ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Ministry of ... gripping look at the religious stand in the sensitive matter of sexual discrimination, ... “The Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing the LGBTQ ...
(Date:9/25/2017)... , ... September 25, 2017 , ... The trend-spotters, tastemakers, ... REBBL®, maker of organic coconut-milk based super herb drinks, with the new NEXTY Gold ... was the inaugural year for the NEXTY Gold, which is reserved for just those ...
(Date:9/25/2017)... Monica, CA (PRWEB) , ... September 25, 2017 ... ... Me” music video on Thursday, September 28, 2017 to deliver a powerful message ... It On film Franchise. , Feature film writer/director Robert Adetuyi (Beat the World, ...
(Date:9/24/2017)... , ... September 23, 2017 , ... Throughout the United ... harm. , Every day, physicians, nurses and other providers work to give the ... innovative industry processes. , But U.S. Senators today are threatening to tie our ...
Breaking Medicine News(10 mins):